[go: up one dir, main page]

WO2013003353A3 - Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages - Google Patents

Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages Download PDF

Info

Publication number
WO2013003353A3
WO2013003353A3 PCT/US2012/044206 US2012044206W WO2013003353A3 WO 2013003353 A3 WO2013003353 A3 WO 2013003353A3 US 2012044206 W US2012044206 W US 2012044206W WO 2013003353 A3 WO2013003353 A3 WO 2013003353A3
Authority
WO
WIPO (PCT)
Prior art keywords
vlps
virus
particles
valency
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/044206
Other languages
French (fr)
Other versions
WO2013003353A2 (en
Inventor
David S. Peabody
Bryce Chackerian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNM Rainforest Innovations
Original Assignee
STC UNM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STC UNM filed Critical STC UNM
Publication of WO2013003353A2 publication Critical patent/WO2013003353A2/en
Publication of WO2013003353A3 publication Critical patent/WO2013003353A3/en
Priority to US14/104,844 priority Critical patent/US20140106982A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 or PP7 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on bacteriophage VLPs, especially MS2 or PP7 VLPs over a wide range, from few than one- on average- to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of bacteriophage such as MS2 or PP7 modified by insertion of a heterologous peptide, optionally comprising a carbohydrate mimotope, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates bacteriphage mRNA.
PCT/US2012/044206 2009-12-31 2012-06-26 Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages Ceased WO2013003353A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/104,844 US20140106982A1 (en) 2009-12-31 2013-12-12 Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503188P 2011-06-30 2011-06-30
US61/503,188 2011-06-30

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/520,057 Continuation-In-Part US9365831B2 (en) 2009-12-31 2010-12-31 Plasmids and methods for peptide display and affinity-selection on virus-like particles of RNA bacteriophages
PCT/US2010/062638 Continuation-In-Part WO2011082381A2 (en) 2009-12-31 2010-12-31 Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/104,844 Continuation US20140106982A1 (en) 2009-12-31 2013-12-12 Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages

Publications (2)

Publication Number Publication Date
WO2013003353A2 WO2013003353A2 (en) 2013-01-03
WO2013003353A3 true WO2013003353A3 (en) 2013-09-19

Family

ID=47424765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/044206 Ceased WO2013003353A2 (en) 2009-12-31 2012-06-26 Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages

Country Status (1)

Country Link
WO (1) WO2013003353A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549976B1 (en) 2012-11-16 2017-01-24 Stc.Unm Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles
US9943580B2 (en) 2013-09-12 2018-04-17 Stc.Unm Malaria vaccine
CN103923887A (en) * 2014-04-16 2014-07-16 辽宁医学院 Pseudoviral particle containing hepatitis e virus RNA (Ribose Nucleic Acid) fragment and preparation method thereof
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
DK3368068T3 (en) 2015-10-30 2021-02-22 Univ Copenhagen Virus-like particles with efficient epitope display
CN109152811A (en) 2015-12-18 2019-01-04 阿吉尔瓦克斯公司 Composition relevant to xCT peptide and method
CN105969786B (en) * 2016-06-07 2019-08-02 博奥生物集团有限公司 A kind of plasmid for expressing MS2 phage capsid protein and maturase
WO2025007075A1 (en) * 2023-06-29 2025-01-02 Life Technologies Corporation Molecules resistant to nuclease digestion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100880477B1 (en) * 1999-10-14 2009-01-28 더 다우 케미칼 캄파니 Virus Particles with Exogenous Internal Epitopes
JP2010538619A (en) * 2007-09-11 2010-12-16 ユニベルシテ ラヴァル Malva mosaic virus and virus-like particles and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100880477B1 (en) * 1999-10-14 2009-01-28 더 다우 케미칼 캄파니 Virus Particles with Exogenous Internal Epitopes
JP2010538619A (en) * 2007-09-11 2010-12-16 ユニベルシテ ラヴァル Malva mosaic virus and virus-like particles and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRYCE CHACKERIAN ET AL.: "Peptide Epitope Identification by Affinity Selection on RNA bacteriophage MS2 Virus-Like Particles.", JOURNAL OF MOLECULAR BIOLOGY, vol. 409, no. ISSUE, 9 April 2011 (2011-04-09), pages 225 - 237 *
DAVID S. PEABODY ET AL.: "Immunogenic Display of Diverse Peptides on Virus-like Particles of RNA Phage MS2.", JOURNAL OF MOLECULAR BIOLOGY, vol. 380, no. ISSUE, 2008, pages 252 - 263 *
JERRI C. CALDEIRA ET AL.: "Thermal stability of RNA phage virus-like particles displaying foreign peptides.", JOURNAL OF NANOBIOTECHNOLOGY., vol. 9, no. 2, 24 May 2011 (2011-05-24), pages 1 - 7 *
VANCE P. LOCHRIDGE ET AL.: "Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions.", JOURNAL OF GENERAL VIROLOGY, vol. 86, 2005, pages 2799 - 2806 *

Also Published As

Publication number Publication date
WO2013003353A2 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
WO2011082381A3 (en) Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages
WO2013003353A3 (en) Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages
MX349924B (en) Chimeric influenza virus-like particles comprising hemagglutinin.
MX394097B (en) PRODUCTION OF VIRUS-LIKE PARTICLES IN PLANTS.
WO2013082317A8 (en) Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
CA2817005A1 (en) Rabies glycoprotein virus-like particles (vlps)
WO2017136575A8 (en) Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
WO2011034953A3 (en) Lassa virus-like particles and methods of production thereof
PH12020550169A1 (en) Isothiocyanate containing brassicaceae products and method of preparation thereof
WO2008024427A3 (en) A virus-like platform for rapid vaccine discovery
SG10201808837RA (en) Anti-egfr antibodies and antibody drug conjugates
WO2017040387A3 (en) Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
HK1203972A1 (en) Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015191693A3 (en) Method for gene editing
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
SG10201805197VA (en) Compositions and methods using capsids resistant to hydrolases
WO2012165815A3 (en) Nano-vehicle derived from tumor tissue, and cancer vaccine using same
MX2016009149A (en) IMPROVED VARIATIONS OF ENZYMES.
PH12020500526A1 (en) Paramyxoviridae expression system
MX2013013228A (en) Virus-like particles and process for preparing same.
HK1253310A1 (en) Surface display of antigens on gram-negative outer membrane vesicles
NZ622731A (en) Increasing virus-like particle yield in plants
BR112014017242A2 (en) immunogenic hpv l2-containing vlps and related compositions and methods
WO2013055326A3 (en) Vaccines for human papilloma virus and methods for using the same

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 12805362

Country of ref document: EP

Kind code of ref document: A2